Similarly, in addition to controlling hyperglycemia, SGLT2 also plays a role in reducing weight loss, controlling hypertension, increasing urinary sodium excretion and reducing edema by reducing sympathetic activity, improving insulin resistance (142), regulating renal sodium and urate transport and excretion in MetS patients (143, 144). The gene discussed is SLC5A2; the disease is Insulin resistance.